Evidence map›Paper›PMID 38639833›Full record

ReviewGeroScience2024

Atherosclerotic burden and cerebral small vessel disease: exploring the link through microvascular aging and cerebral microhemorrhages.

Anna Csiszar, Anna Ungvari, Roland Patai, Rafal Gulej, Andriy Yabluchanskiy, Zoltan Benyo, Illes Kovacs, Peter Sotonyi, Angelia C Kirkpartrick, Calin I Prodan and 6 more

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in GeroScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07651787 (Neurovascular and Mitochondrial Mechanisms of Transcranial Photobiomodulation in Vascular Mild Cognitive Impairment), which is not on this map. Cited by 47 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 3 pooled it
19.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07651787 narecruitingnot on this mapstarted 2025, after this paper: background citation

Neurovascular and Mitochondrial Mechanisms of Transcranial Photobiomodulation in Vascular Mild Cognitive Impairment

TypeinterventionalSponsorUniversity of OklahomaRan2025 to 2026Enrolled40ConditionsMild Cognitive Impairment (MCI), Amyloid PathologyArmsActive Vielight Neuro RX-Duo device -Active transcranial photobiomodulation, Sham Vielight Neuro RX-Duo device -Sham transcranial photobiomodulation
3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Effects of NADThe Journal of pharmacology and experimental therapeutics · 2025
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Multi-contrast optical coherence tomography forBiomedical optics express · 2026
    Article
  12. Article
  13. Observational
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Anna Csiszar *Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Anna Ungvari *Department of Public Health, Semmelweis University, Semmelweis University, Budapest, Hungary. Ungann2004@gmail.com.
Roland Patai *Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Rafal GulejVascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Andriy YabluchanskiyVascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Zoltan BenyoInstitute of Translational Medicine, Semmelweis University, 1094, Budapest, Hungary.
Illes KovacsDepartment of Ophthalmology, Semmelweis University, 1085, Budapest, Hungary.
Peter SotonyiDepartment of Vascular and Endovascular Surgery, Heart and Vascular Centre, Semmelweis University, 1122, Budapest, Hungary.
Angelia C KirkpartrickVeterans Affairs Medical Center, Oklahoma City, OK, USA.
Calin I ProdanVeterans Affairs Medical Center, Oklahoma City, OK, USA.
Eric M LiottaInternational Training Program in Geroscience, Doctoral College/Department of Public Health, Semmelweis University, Budapest, Hungary.
Xin A ZhangDepartment of Physiology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA.
Peter TothVascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Stefano TarantiniVascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Farzaneh A SorondDepartment of Neurology, Division of Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Zoltan UngvariVascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Semmelweis University · HUUniversity of Oklahoma Health Sciences Center · USVeterans Health Administration · USNorthwestern University · USUniversity of Pecs · HU

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ROBERT S. MANNEL · 2018 to 2026
$27.1M
Cerebral Small Vessels in Motor and Cognitive Decline: Neuroimaging Signatures of Vulnerability & ResilienceR01NS085002 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FARZANEH A SOROND · 2014 to 2026
$3.8M
Age-related vascular cognitive impairment: role of endothelial senescenceR01AG068295 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CSISZAR, ANNA, UNGVARI, ZOLTAN ISTVAN · 2020 to 2024
$1.8M
How Tetraspanins Regulate SepsisR01GM135547 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ZHANG, XIN A · 2020 to 2023
$1.4M
Cerebral Autoregulation, Metabolic derangement, and Edema in Encephalopathy Outcome (CAMEEO)K23AG078705 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Eric Michael Liotta · 2023 to 2026
$762k
How Endothelial Tetraspanins Inhibit InflammationR01HL173312 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ZHANG, XIN A · 2025 to 2025
$730k
CSRD VA I01 CX000340European University for Well-Being 101004093NCI NIH HHS P30 CA225520NHLBI NIH HHS R01 HL173312NIA NIH HHS K23 AG078705NIA NIH HHS R01 AG068295NIA NIH HHS R01AG068295NIGMS NIH HHS R01 GM135547NINDS NIH HHS R01 NS085002
6 · The paper itself

Abstract

Cerebral microhemorrhages (CMHs, also known as cerebral microbleeds) are a critical but frequently underestimated aspect of cerebral small vessel disease (CSVD), bearing substantial clinical consequences. Detectable through sensitive neuroimaging techniques, CMHs reveal an extensive pathological landscape. They are prevalent in the aging population, with multiple CMHs often being observed in a given individual. CMHs are closely associated with accelerated cognitive decline and are increasingly recognized as key contributors to the pathogenesis of vascular cognitive impairment and dementia (VCID) and Alzheimer's disease (AD). This review paper delves into the hypothesis that atherosclerosis, a prevalent age-related large vessel disease, extends its pathological influence into the cerebral microcirculation, thereby contributing to the development and progression of CSVD, with a specific focus on CMHs. We explore the concept of vascular aging as a continuum, bridging macrovascular pathologies like atherosclerosis with microvascular abnormalities characteristic of CSVD. We posit that the same risk factors precipitating accelerated aging in large vessels (i.e., atherogenesis), primarily through oxidative stress and inflammatory pathways, similarly instigate accelerated microvascular aging. Accelerated microvascular aging leads to increased microvascular fragility, which in turn predisposes to the formation of CMHs. The presence of hypertension and amyloid pathology further intensifies this process. We comprehensively overview the current body of evidence supporting this interconnected vascular hypothesis. Our review includes an examination of epidemiological data, which provides insights into the prevalence and impact of CMHs in the context of atherosclerosis and CSVD. Furthermore, we explore the shared mechanisms between large vessel aging, atherogenesis, microvascular aging, and CSVD, particularly focusing on how these intertwined processes contribute to the genesis of CMHs. By highlighting the role of vascular aging in the pathophysiology of CMHs, this review seeks to enhance the understanding of CSVD and its links to systemic vascular disorders. Our aim is to provide insights that could inform future therapeutic approaches and research directions in the realm of neurovascular health.

Indexed as

AgingCerebral Small Vessel DiseasesAgedAtherosclerosisCerebral HemorrhageHumansMicrocirculationMicrovesselsRisk FactorsAgingArteriosclerosisAtherosclerosisBlood–brain barrierLeukoaraiosisMicrobleedPeripheral artery diseaseStrokeVascular dementiaWhite matter hyperintensitiesWhite matter injury

Identifiers

PMID38639833
PMCPMC11336042
OpenAlexW4394962187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.